ClinicalTrials.gg
Not yet recruitingNCT07876817SERENEUpdated Oct 15, 2026

A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive

A Phase 4 interventional study of Durvalumab and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC), sponsored by AstraZeneca. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing durvalumab in Urinary Bladder Neoplasms — 4 open to participants now, 12 under way, 3 of them phase 3. durvalumab · Urinary Bladder Neoplasms.

Planned enrollment
9th of 19
50 · median 39
Started
2026
the only one that year
Phase 4
Only one
of the 19
Primary completion
2029-01
later than 11 of 11 live
Registered
19th of 19
by date
Lead sponsor
5 of 19
AstraZeneca

Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 4, reaches primary completion later than 11 of the 11 other live ones, and was the 19th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

4 of the 19 studies testing durvalumab in Urinary Bladder Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing durvalumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 4, Single Arm Study To Assess The Safety and tolerability of Perioperative Durvalumab in Combination with Neoadjuvant Gemcitabine Plus Cisplatin Treatment Followed by radical cystectomy and Durvalumab alone as Treatment in Indian Patients with Muscle-Invasive Bladder Cancer. It is to be conducted in compliance with a condition of approval specified by Health Authority of India following the addition of this indication to the approved prescribing information. A phase IV clinical trial to Asses the safety profile of this regimen in patients from India and subsequently, any regulatory action resulting from the review should be complied.

03

Conditions studied

  • Muscle-Invasive Bladder Cancer (MIBC)

Keywords

  • Muscle-Invasive Bladder Cancer
  • MIBC
  • Durvalumab
  • Gemcitabine
  • Cisplatin
  • Neoadjuvant Therapy
  • Adjuvant Therapy
  • Perioperative
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • * Participant must be ≥18 years of age inclusive.
  • * Patients with or cytologically documented muscle-invasive TCC (also known as UC) of the bladder.
  • * Patients with transitional cell and mixed transitional/non-transitional cell histologies.
  • * Patients with clinical tumour stage T2-T4aN0/1M0.
  • * Medically fit for treatment with therapy prior to radical cystectomy.
  • * Medically fit to undergo a radical cystectomy at time of enrolment.
  • * Have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC.
  • * Body weight >30 kg.
  • * Male participants must use a condom plus an additional method.
  • * Female participants must be or have evidence of nonchildbearing status.
  • * Capable of giving signed .
  • * Must have a of at least 12 weeks at Enrollement.
  • * Adequate bone marrow function ( ≥ 9.0 g/dL, ≥ 1.5 × 10\^9/L, count ≥100 x 10\^9/L).
  • * Adequate renal function ( (CrCL) > 40 mL/min).
  • * Adequate hepatic function (Total ≤ 1.5 × , and ALT ≤2.5 x ULN).

Exclusion criteria

Exclusion Criteria:

  • * Evidence of lymph node (N2-3) or TCC/UC (M1), extravesical TCC/UC (T4b), or primary non-bladder TCC/UC.
  • * Any unresolved toxicity Grade ≥2 from previous anticancer therapy except for alopecia, vitiligo, and specified laboratory values.
  • * Major surgical procedure within 2 weeks of starting study treatment.
  • * Requirement for a nephroureterectomy at the time of enrollement for tumour of the mid ureter, renal pelvis, or collecting system.
  • * Inoperable tumour(s) with fixation to the pelvic wall on clinical exam.
  • * History of allogeneic organ transplantation that requires use of agents.
  • * Active or previously documented or inflammatory disorders.
  • * Uncontrolled intercurrent illness.
  • * History of another primary , with exceptions.
  • * Resting indicating uncontrolled, potentially reversible cardiac conditions.
  • * History of active primary immunodeficiency.
  • * History of a myocardial infarction within 6 months prior to enrollement.
  • * Any systemic disease or medical condition that could interfere with the study.
  • * Any clinically significant systemic disease or medical condition that could interfere with the study.
  • * positive.
  • * Any medical to platinum (Cisplatin)-based doublet chemotherapy.
  • * Concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment.
  • * Prior exposure to immune-mediated therapy (with exclusion of BCG).
  • * Current or prior use of immunosuppressive medication within 14 days before the first dose of Durvalumab, with exceptions.
  • * Prior pelvic radiotherapy treatment within 2 years of enrollement to study.
  • * Receipt of within 30 days before the first dose of study treatment.
  • * Concomitant use of known strong or moderate inhibitors.
  • * Concomitant use of known strong or moderate CYP3A inducers.
  • * Participation in another clinical study with a study intervention administered in the last 30 days.
  • * Involvement in the planning and/or conduct of the study.
  • * Involvement in the planning and/or conduct of the study.
  • * For females only - currently pregnant or breastfeeding.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Treatment (Durvalumab + Gemcitabine + Cisplatin)

    On Day 1 of each cycle, Durvalumab 1500 mg IV followed by Cisplatin 70 mg/m2 and gemcitabine 1000 mg/m2; on Day 8 Gemcitabine 1000 mg/m2; given every 21 days for 4 cycles. For patients with borderline renal function, a split dose of Cisplatin (35 mg/m2 on Days 1 and 8) may be used. After radical cystectomy Durvalumab 1500 mg IV every 4 weeks (Q4W) for up to 8 cycles (29 weeks).

    Drug: Durvalumab · Drug: Gemcitabine · Drug: Cisplatin

Interventions

  • Solution for IV infusion, 1500 mg/vial. Administered at 1500 mg IV every 3 weeks during the neoadjuvant phase and every 4 weeks during the adjuvant phase.

    Also known as: IMFINZI

  • Solution for IV infusion. Administered at 1000 mg/m² on Day 1 and Day 8 of each 21-day neoadjuvant cycle.

  • Solution for IV infusion. Administered at 70 mg/m² on Day 1 of each 21-day neoadjuvant cycle. A split dose of 35 mg/m² on Days 1 and 8 may be used for patients with borderline renal function.

06

What researchers measure

Primary outcomes

  1. Number of subjects experiencing adverse events (AEs)

    The number of subjects experiencing adverse events (AEs), with categorization of AEs by system organ class, preferred term, and CTCAE grade.

    Time frame: Throughout the study, up to approximately 66 weeks

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs) and Adverse Drug Reactions (ADRs)

    Percentage of Subjects with SAEs, TEAEs \& with ADRs during the study.

    Time frame: Throughout the study, up to approximately 66 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Jan 2029, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartEst.
Oct 20, 2026
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07876817
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 20, 2026 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Gemcitabine · Cisplatin

Start the discussion